Yun Ka Yeong, Han Si Eun, Kim Seung Chul, Joo Jong Kil, Lee Kyu Sup
Medical Research Institute, Pusan National University Hospital, Busan, Korea.
Department of Obstetrics and Gynecology, Pusan National University School of Medicine, Busan, Korea.
Obstet Gynecol Sci. 2017 Jan;60(1):133-137. doi: 10.5468/ogs.2017.60.1.133. Epub 2017 Jan 19.
Pregnancy-related osteoporosis is a very rare condition characterized by the occurrence of fracture during pregnancy or the puerperium. Despite its relative rarity, it can be a dangerous condition that causes severe back pain, height loss and disability. Normal physiologic changes during pregnancy, genetic or racial difference, obstetrical history and obstetrical disease, such as preterm labor or pregnancy-induced hypertension, are presumed risk factors of pregnancy-related osteooporosis. However, exact etiology and pathogenesis are uncertain. The management and natural history are still poorly defined. Traditional medications for osteoporosis are calcium/vitamin D and bisphosphonate. Concerns with bisphosphonate include accumulation in bone and fetal exposure in subsequent pregnancies. The newly developed medication, teriparatide, has shown good results. We report six cases of pregnancy-related osteoporosis and spinal fracture with literature review.
妊娠相关性骨质疏松症是一种非常罕见的病症,其特征是在妊娠期间或产褥期发生骨折。尽管相对罕见,但它可能是一种危险的病症,会导致严重的背痛、身高降低和残疾。妊娠期间的正常生理变化、遗传或种族差异、产科病史以及产科疾病,如早产或妊娠高血压,被认为是妊娠相关性骨质疏松症的危险因素。然而,确切的病因和发病机制尚不确定。其治疗和自然病程仍未明确界定。传统的骨质疏松症治疗药物是钙/维生素D和双膦酸盐。双膦酸盐的问题包括在骨骼中的蓄积以及对后续妊娠中胎儿的暴露影响。新开发的药物特立帕肽已显示出良好的效果。我们报告6例妊娠相关性骨质疏松症合并脊柱骨折的病例并进行文献复习。